Online inquiry

IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6803MR)

This product GTTS-WQ6803MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets STEAP1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_012449.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 26872
UniProt ID Q9UHE8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6803MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15117MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SYD985
GTTS-WQ631MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ2191MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ10573MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3127804
GTTS-WQ14151MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ8769MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ14524MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SA-237
GTTS-WQ3579MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1112623
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW